Mesenchymal stem cell therapy for liver disease: current status and future perspectives

Area of Science:

• Regenerative Medicine
• Hepatology
• Cellular Therapy

Background:

• Liver transplantation is the primary treatment for end-stage liver disease but faces limitations due to organ shortages and high costs.
• Cellular therapies, including mesenchymal stem cells (MSCs), are emerging as potential alternatives to liver transplantation.
• MSCs possess unique properties like homing, immunosuppression, and tissue regeneration capabilities, making them suitable for therapeutic applications.

Purpose of the Study:

• To review existing literature on MSC transplantation for liver diseases.
• To discuss future research directions for improving MSC therapy efficacy.

Main Methods:

• Literature review of studies involving MSC transplantation for liver diseases.
• Analysis of MSC properties relevant to liver regeneration and therapy.

Main Results:

• MSCs exhibit properties such as homing, transdifferentiation, immunosuppression, and cellular protection, indicating regenerative potential.
• MSCs can be isolated and expanded ex vivo for clinical use.
• Current literature suggests MSC therapy is a safe and promising alternative for liver diseases, with potential to improve liver function without side effects.

Conclusions:

• MSC therapy is a promising alternative for end-stage liver diseases, offering potential benefits with no reported side effects.
• Further rigorous preclinical and clinical studies are essential to optimize MSC transplantation efficacy for liver conditions.